Coherus Oncology is cutting about 30 percent of its workforce, from roughly 140 to about 100 full-time employees this month, as it narrows development of its investigational combination treatment tagmokitug to esophageal cancer and deprioritises other indications. The company said on its November 9 third quarter call that the reorganisation should reduce quarterly core cash spending by 6 million to 7 million dollars over the next two quarters. Third quarter net revenue was 14.3 million dollars, with LOQTORZI revenue of 14.0 million dollars up 25 percent year on year, against cash and marketable securities of 83.6 million dollars at September 30. BioSpace notes this is the second 30 percent downsizing at the California company in less than two years, following the exit from its biosimilars business.
Vertex Pharmaceuticals will lay off 78 employees at Crinetics Pharmaceuticals’ San Diego headquarters, effective in January, according to a California WARN notice reported by Fierce Pharma on November 10. Crinetics had 594 full-time employees as of February 13, 2026, so the cuts amount to about 13 percent of that workforce, concentrated in corporate functions on BioSpace’s reading of the notice. Vertex completed its acquisition of the endocrine drug developer, worth about 10 billion dollars, on September 1, and its chief operating officer Charles Wagner is leading the integration. The layoffs are the standard post-acquisition removal of duplicated headquarters roles; no research site closure was reported.
A former Eli Lilly sales manager has sued the company in the United States District Court for the Northern District of Texas, in a complaint filed on Monday, November 9 and reported by STAT and Bloomberg Law. Jennifer Mansion, hired as a senior territory manager in Dallas four years ago, alleges that Lilly promoted Mounjaro, approved in 2022 for type 2 diabetes, for weight loss before that use was approved, that a physician touted the drug as a weight loss option at a company-sponsored luncheon, and that the promotion caused Texas Medicaid to disburse improper reimbursements. She claims she was fired in retaliation for complaining, in violation of the False Claims Act. These are allegations in a complaint, not findings; no Lilly response was reported in the sources read in this run.